A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy
A study for patients with Progressive Supranuclear Palsy (PCP) using study drug C2N-8E12
Sponsor: C2N Diagnostics
Enrolling: Male and Female Patients
IRB Number: AAAP6502
U.S. Govt. ID: NCT02494024
Contact: Evelyn Dominguez-Rivera: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: The purpose of this Phase I study is to see whether a single dose of an experimental drug (meaning a drugthat is not approved by the FDA) called C2N-8E12 given into your vein (called intravenous or IV) is safeand well-tolerated in subjects with Progressive Supranuclear Palsy (PSP). C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to remove tau protein. The tau protein is believed to build up to abnormally high levels in the brains of individuals with PSP. This abnormal accumulation is associated with clinical progression of the disease. In addition, this study will also test the effects of C2N-8E12 on cerebrospinal fluid (CSF) and certain blood proteins (including tau) in subjects with PSP. This study uses a placebo that looks like the experimental drug but does not have any active drug in it. This means that 1 out of every 4 subjects (or 25%) who take part in this study will not receive active treatment from their participation.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Have you been diagnosed with Progressive Supranuclear Palsy (PCP)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn Dominguez-Rivera